Trials / Terminated
TerminatedNCT00199264
Efficacy Vulvovaginitis Candida
A Single-Blind, Randomized, Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- J. Uriach and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of albaconazole, as a single oral dose, in women affected by acute non-complicated vulvovaginitis due to Candida spp.
Detailed description
Multi-center, open-label, randomized study, controlled with fluconazole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Albaconazole oral solution |
Timeline
- Start date
- 2004-06-01
- Completion
- 2004-10-01
- First posted
- 2005-09-20
- Last updated
- 2006-10-03
Source: ClinicalTrials.gov record NCT00199264. Inclusion in this directory is not an endorsement.